Kornimate/medical-research-clean huggingface dataset:
role of adverse childhood events and rejection sensitivity on alcohol use in recently withdrawn individuals with alcohol use disorder

Conditions: Alcohol-Induced Disorders; Ostracism

Summary: low utilization of addiction treatment is a public health problem. a number of factors are associated with lack of treatment, including public stigma, self-stigma, and beliefs that people with addiction should solve their problem on their own. stigma exposes individuals to social rejection, which may sustain the anxiety of rejection, and exacerbate certain mental disorders such as addictions. social cognition disorders have been shown to be present in addictions, but one dimension of social cognition, emotional sensitivity to rejection (esr), has been less studied. rejection sensitivity could be considered a critical element in access to care and the relapse process. the study authors hypothesize a role for emotional dysregulation in rejection situations in the relapse of alcohol use disorder in recently withdrawn patients. specifically, they hypothesize that participants with a greater change in negative experience after a rejection situation on a cyberball task, as measured by the negative subscale of the positive and negative affect schedule (panas), will have a higher percentage of days with heavy drinking during the last four weeks to three months of follow-up.


Eligibility criteria:
inclusion criteria: * patient admitted to the grau-du-roi follow-up and rehabilitation care service. * patient abstinent from alcohol for at least 10 days. * the patient must have given their free and informed consent and signed the consent form * the patient must be a member or beneficiary of a health insurance plan exclusion criteria: * other mental health disorder: bipolar disorder, schizophrenia, severe acute depression, borderline personality. * severe substance use disorder (sud). * current suicidal ideation as judged by clinician. * patient unable to give consent. * pregnant or breastfeeding patient. * the subject is participating in a category 1 interventional study, or is in a period of exclusion determined by a previous study * it is impossible to give the subject informed information * the patient is under safeguard of justice or state guardianship

Keywords: adverse childhood experiences rejection
the ms-link™ outcomes study

Conditions: Multiple Sclerosis

Summary: the multiple sclerosis (ms) leadership and innovation network (ms-link™) is comprised of networks working cooperatively to advance multiple sclerosis (ms) science and improve ms participant outcomes. in this study participants will be followed from the time of consent through the lifetime of the study (currently 3 years), unless the participant chooses to withdraw from the study. collection of participant's medical history, including ms and treatment history, will be automated through extraction from the participant's electronic medical record (emr) and other health information systems (for example, radiology). participants will complete patient-reported outcomes (pros) and other health-related information digitally. participating participants will have access to their own data in an ongoing manner via a web-based participant portal.


Eligibility criteria:
inclusion criteria: * participants willing and able to provide written informed consent * participants willing to be contacted while participating in the study for recruitment into sub-studies that may be relevant to them * participants willing and able to complete pros on a monthly basis and document events of interest as they occur * participants willing to participate in additional follow up at the site for at least three years exclusion criteria: * unable to complete questionnaires in english * unable to consistently access the internet * participants participating in interventional clinical drug trials at baseline

Keywords: expanded disability status scale multiple sclerosis patient reported outcomes measurement information system
national registry of adult heart failure patients with complex congenital heart disease: systemic right ventricle and single ventricle treated with sacubitril/valsartan

Conditions: Complex Congenital Heart Disease

Summary: heart failure in adults with congenital heart disease is a major cause of morbidity and mortality. patients with systemic right ventricle (srv) and single ventricle (sv) are particularly at risk1, 2, 3. there are no specific recommendations for the management of heart failure in adults with congenital heart disease, whose management is based on "general cardiology" recommendations4,5. sacubitril/valsartan is validated as a treatment for heart failure in adults with acquired pathological left ventricular dysfunction (left ventricular ejection fraction (lvef) \< 40%, new york heart association (nyha) functional class ii and iii despite optimal heart failure therapy)7. although this molecule is used in current practice in patients with congenital heart disease, published data are limited 6-10. the aim of our work is to describe the efficacy and tolerability of sacubitril/valsartan in the treatment of chronic heart failure on vds and vu through an observational, prospective, multicenter registry. the latest heart failure treatment guidelines, updated in 202111, recommend the addition of type 2 sodium-glucose co-transport inhibitors in heart failure patients with impaired ejection fraction (class ia recommendation). two molecules are used in current practice: dapagliflozin and empagliflozin, at a single dosage of 10 mg/day. we will also be collecting data on the efficacy and safety of isglt2. it should be noted that, for practical reasons, there may be a delay between the end of the 1st study period (isacc1) of one year and the start of the 2nd study period (isacc2). follow-up examinations carried out during the study period will not differ from those currently recommended in current practice5.


Eligibility criteria:
inclusion criteria: * - patients ≥ 18 years of age * congenital heart disease with systemic right ventricle (d-tgv after atrial switch (mustard or senning surgery) or double mismatch), single ventricle of right or left morphology * systemic ventricular ejection fraction ≤ 40% (on cardiac magnetic resonance imaging (mri) less than 12 months old). in case of contraindication to mri, lvef ≤ 40% if systemic left ventricle or surface shortening fraction ≤ 35% if vds12 (examination less than 12 months old). * nyha ii or iii * on optimal heart failure therapy: ace inhibitor or arb2 for ≥ 4 weeks, at maximum tolerated dose. whether or not combined with beta-blockers and maximum-tolerated-dose mineralocorticoid receptor antagonists. * cardiopulmonary exercise test (cpet) within the last 12 months exclusion criteria: * - other congenital heart disease * inability to perform cpeth * immuno-allergic reaction, history of angioedema on ace inhibitors or arb2 inhibitors * symptomatic arterial hypotension or bps \< 100 mhg * renal insufficiency (gfr \ 5.4 mmol/l, severe hepatic insufficiency (child-pugh class c) * pregnancy or breast-feeding * opposition to use of patient data * type 1 diabetes if on isglt2
nevada environmental tobacco smoke and health study

Conditions: Cardiovascular Disease; Cancer

Summary: workplace exposure to secondhand cigarette smoke or environmental tobacco smoke (ets)is widespread, effecting between 19 and 49% of the u.s. workforce. the first part of this study is designed to test whether exposure to ets in the workplace effects a person's risk of developing chronic diseases such as cardiovascular disease and cancer. the second part of this study is designed to test whether antioxidant supplementation in this group of ets exposed individuals can reduce their risk of developing chronic disease. the study will look at 375 non-smokers who either work on a casino floor or as bartenders or cocktail servers. initial baseline data will be collected (questionnaires and blood samples taken) and the subjects will be randomized into one of three groups, placebo, low antioxidant supplementation and high antioxidant supplementation. they will be followed over a two-year period, coming in for follow-up testing every six months. statistical analysis will be conducted to see whether this group of ets exposed individuals has a greater risk of developing chronic disease and whether the use of antioxidant supplements can moderate any risks.


Eligibility criteria:
inclusion criteria: non-smoker work in a casino - on the casino floor or work as a bartender or cocktail server for at least 1 year do not take antioxidant supplements healthy - not diagnosed with any major chronic diseases. exclusion criteria: blood pressure sbp\>200,\ 100, \ 120, \ 400 triglycerides \>700 blood cotinine \>10 ng/ml bmi \>35

Keywords: oxidative stress cardiovascular disease cancer
korean linguistic adaptation of rhinitis controlled assessment test

Conditions: Rhinitis

Summary: korean linguistic adaptation of rhinitis controlled assessment test (rcat).

check the korean version of rhinitis controlled assessment tests, the total non-symptom scores (total nasal symptoms score, tnss), rhinitis-related quality of life (rqlq), rhinitis controlled degree, severity, and after study enrollment and 4 weeks treatment.

Eligibility criteria:
inclusion criteria: 1. adults over 19 years 2. past medical history and allergy skin test or who have been diagnosed with allergic or non-allergic rhinitis, based on serum specific immunoglobulin e . 3. people who have experienced symptoms of rhinitis within 12 months from the time of study enrollment. 4. people who have rhinitis symptoms requiring medication at the time of study enrollment. 5. people who can read and write korea language. 6. people who signed a written consent form approved by the institutional review board of their respective organizations to participate in this study freely hearing to explain fully the purpose for the contents of this study prior to participation in research. exclusion criteria: 1. people diagnosed with rhinitis medicamentosa. 2. people determined that bacterial or viral respiratory infection at the time of study enrollment. 3. people who have evidence of nasal infection 4. people associated anatomical abnormality that causes severe nasal congestion as deviation of nasal septum. 5. people determined that acute or chronic sinusitis according to the researchers determined. 6. in case that pregnancy test is positive, or ambiguous conclusions among female patients. 7. people deemed unsuitable for clinical trial participation due to other reasons.
the effect of tranexamic acid on postpartum hemorrhage during and after cesarean delivery

Conditions: Hemorrhage

Summary: intravenous tranexamic acid is used to reduce the hemorrhage during and after cesarean delivery in a double blind randomized placebo controlled trial.


Eligibility criteria:
inclusion criteria: 1. term pregnancy 2. single fetus 3. maximally only one previous cesarean delivery exclusion criteria: 1. more than one previous cesarean delivery 2. hx of other abdominal or pelvic surgery 3. hx of medical disorders 4. hx of thromboembolic disorders 5. polyhydramnios 6. macrosomia 7. preeclampsia 8. hx of sensitivity to tranexamic acid 9. abnormal pt, ptt, pt or inr

Keywords: cesarean delivery tranexamic acid hemorrhage spinal analgesia 1-the amount of hemorrhage during cesarean delivery 2-the amount of hemorrhage in the first 2 hours of cesarean delivery 3-the amount of hemorrhage in the first 24 hour after cesarean delivery
needle-free injection of lidocaine for local anesthesia prior to trigger digit injection

Conditions: Trigger Finger

Summary: jet-injection (j-tip) is a rapid, minimally invasive delivery system that can be used for the subdermal injection of lidocaine solution for anesthetic purposes. the device has been found effective in pain reduction during iv catheterization in adults and children and lumbar puncture in children when compared to placebo saline-jet injection. \[1-4\]. we believe that administering local anesthetic via j-tip prior to triamcinolone(40 mg/ml) injection could mitigate pain that occurs during and immediately following injection while preserving the post-injection pain relief of anesthetic injection. furthermore, pre-placement of the jet-injected local anesthetic may obviate the need for the inclusion of local anesthetic into the triamcinolone injection. this would decrease the amount of fluid injected, which could have positive pain modulation by decreased tissue disruption. objective: to evaluate the effectiveness of needle free jet injection (j-tip) administration of 2% lidocaine in reduction of the pain experienced during trigger digit 40 mg/ml triamcinolone injection. hypothesis: needle free jet injection (j-tip) administration of 2% lidocaine will prove an equal or superior means of pain reduction when compared to 2% lidocaine injection in the setting of trigger digit triamcinolone injections.


Eligibility criteria:
inclusion criteria: * patients who present to the hand clinic at brigham and women's hospital or brigham and women's faulkner hospital, are 18 years of age or older and are indicated for a trigger digit steroid injection will be eligible for participation
association of centre of excellence self- administered questionnaire score and frailty levels

Conditions: Frailty; Cognitive Decline; Injuries; Fall Injury

Summary: this study evaluates the frailty and the health adverse events in the population of the canadian longitudinal study on aging. it will be used the centre of excellence self-administered questionnaire (cesam) which assesses frailty of older adults by providing a score and a of frailty in 4 levels.

age is broadly recognized to confer a risk for health adverse outcomes, but it is an insensitive and non-specific measure for use in individual decision-making. frailty has been emerging to take its rightful place as a better measure for over past decades. despite general consensus that the concept of frailty is clinically useful, the lack of agreement on its definition and the challenge of its measurement by front-line health providers mean that frailty remains only 'their apparent' to chronological age as a criterion to select older persons at risk.

Eligibility criteria:
inclusion criteria: * being 65 years and over * being enrolled in the canadian longitudinal study on aging exclusion criteria: * never being enrolled in the canadian longitudinal study on aging * undisclosed health adverse events
exercise adherence of home-based cardiac rehabilitation

Conditions: Coronary Artery Disease

Summary: the study explored the influencing factors of exercise adherence of home-based cardiac rehabilitation in patients with coronary artery disease.

the study used a qualitative exploratory design. informants were recruited by purposive sampling. semi-structured individual interviews were conducted among patients with coronary artery disease and medical professionals in home-based cardiac rehabilitation.

Eligibility criteria:
inclusion criteria: * diagnosis of coronary artery disease; * age ≤75 years old; * participated in home-based cardiac rehabilitation ≥12 weeks; * have good language skills; * volunteer to participate in this study. exclusion criteria: * have other serious acute or chronic diseases; * a previous history of mental illness or a positive family history of mental illness; * have severe audio-visual or speech impairments that may affect understanding and answering questions.

Keywords: coronary artery disease home-based cardiac rehabilitation exercise adherence
a study of pressure waveform analysis in coronary artery-ii

Conditions: Ischemic Heart Disease

Summary: the goal of this observational study is to test the feasibility of intracoronary adenosine administration during coronary flow reserve(cfr) and index of microcirculatory resistance(imr) assessment in a population with angina. the main questions it aims to answer are: * repeatability of cfr and imr assessment while hyperemia with intracoronary adenosine was administered. * evaluate the correlation of the intrinsic signal of coronary waveform versus physiologic ischemia, while defined by fractional flow reserve(ffr) and cfr respectively. * the predictive value of ffr, cfr, and imr on major adverse cardiovascular outcomes in 3 years participants will undergo ffr, cfr, and imr assessments in the catheterization laboratory of the national taiwan university hospital hsin-chu branch, then clinical events follow up for 3 years.


Eligibility criteria:
inclusion criteria: * participants with angina exclusion criteria: * severe valvular heart disease * history of asthma * heart rate less than 50 beats per minute * systolic blood pressure less than 90 mmhg
phase i trial to investigate cafusertib hydrochloride in combination with low dose cytarabine in chinese patients with acute myeloid leukaemia (aml)

Conditions: Leukemia, Myeloid, Acute

Summary: to investigate safety, tolerability of cafusertib combination with low dose cytarabine (ld-ara-c) in chinese patients with relapsed/refractory aml that are not eligible for conventional or intensive treatment. the dose of cafusertib will be escalated to determine the dose limiting toxicity (dlt) and the maximum tolerated dose (mtd) of cafusertib in combination with ld-ara-c in aml patients. at the same time, pharmacokinetic characteristics and preliminary efficacy of cafusertib will be observed in aml patients. to determine the recommended dosage regimen for phase ii.


Eligibility criteria:
inclusion criteria: * signed written informed consent consistent with chinese good clinical practice. * male or female patients of age \>/= 18 years at the time of informed consent. * patients with relapsed/refractory aml ineligible for conventional or intensive treatment. * eastern cooperative oncology group performance status score 0 - 2 at screening. * life expectancy of at least 3 months. * adequate hepatic, renal and metabolic function parameters: serum total bilirubin ≤1.5 x upper limit of normal, aspartate transaminase (ast) , alanine transaminase (alt) ≤2.5 x upper limit of normal; creatinine clearance rate ≥60ml/min, serum creatinine ≤1.0 x upper limit of normal; relatively normal ecg(electrocardiogram), qtc\ 50%. * patients who can comply with the trial and follow-up procedures. exclusion criteria: * patients had received cafusertib hydrochloride or other plk inhibitors. * patients with apl. * patients with central nervous system leukemia. * need to continue using cytokine therapy at screening. * patients participated in other clinical trials within 4 weeks prior to enrollment. * patient with severe infection. * patients with myocardial infarction had occurred within six months prior to enrollment. * severe heart disease, including nyha class ii cardiac dysfunction and above. * patients with hiv infection or acute and chronic viral hepatitis. * severe gastrointestinal disorders (bleeding, infection, obstruction or greater than grade 1 diarrhea). * a previous history of neurological or psychiatric disorders, including epilepsy or dementia. * concomitant medications with cyp3a4 inhibitors, inducers or substrates; women pregnant or breast feeding. * subject is thought unfit for this study by investigator.

Keywords: aml phase1 mtd cafusertib
impact of colchicine therapy on arrhythmia recurrence after acute pericardial effusion

Conditions: Pericardial Effusion

Summary: the effects colchicine administration for acute pericardial effusion after radiofrequency catheter ablation (rfca) of atrial fibrillation on the recurrences of arrhythmia.

rfca was started as a rhythm control of atrial fibrillation about 10 years before and the superiority of rfca to medical treatment has been continuously reporting, so rfca is globally performed nowadays. acute pericardial effusion could occur during rfca as complication, that might be developed to cardiac tamponade needed immediate pericardiocentesis. the inflammation developed after pericardiocentesis might be associated with the recurrences of atrial fibrillation, it could be presumed by the frequent occurrence of atrial fibrillation after open-heart surgery. the inflammation can be suppressed by administration of colchicine and the effects of colchicine have been proven to decrease the development of atrial fibrillation.

Eligibility criteria:
inclusion criteria: * patients needed to pericardiocentesis during rfca for paroxysmal or persistent atrial fibrillation. exclusion criteria: * hypersensitivity on colchicine * the existence of intra-cardiac thrombus on trans-esophageal echocardiography * pregnancy

Keywords: pericardial effusion colchicine arrhythmia recurrence pericardiocentesis
imrt-sib and capecitabine in preoperative rectal cancer treatment

Conditions: Rectal Carcinoma

Summary: rationale: using small radiation beamlets of different intensity, imrt (intensity modulated radiation therapy) allows shaping the dose around planning target volume with better sparing of normal tissue comparing to 3d conformal radiotherapy. it allows daily delivery of higher dose to the tumor with simultaneous integrated boost (sib), consequently shortening total treatment time with potentially better response to treatment. in advanced rectal adenocarcinoma excellent response to preoperative radiochemotherapy with complete eradication of the primary tumor observed in the histopathological specimen (pathological complete response, pcr) correlates with a favorable overall prognosis, so trying to achieve better response to preoperative treatment with higher pcr seams feasible. purpose:the hypothesis of this study is that in preoperative radiochemotherapy for locally advanced rectal adenocarcinoma shortening of the total treatment time with imrt-sib to 22 daily fractions concomitant with capecitabine results in an improved pcr rate from 9% (slovenian trial) to 25%. secondary objectives are to evaluate pathological down-staging rate, histopathological r0 resection rate, sphincter preservation rate, perioperative surgical complication rate, local control, disease-free survival (dfs), overall survival (os), late toxicity and quality of life.


Eligibility criteria:
inclusion criteria: * biopsy-proven newly diagnosed primary rectal adenocarcinoma * locally advanced tumor fulfilling at least one of the following criteria on pelvic mri: * t ≥ 3 or * n ≥ 1 * positive mesorectal fascia (mrf), i.e. tumor or lymph node one mm or less from the mesorectal fascia * tumor located od 0 - 15 cm above anocutaneous junction or below peritoneum * age 18 years and more * signed informed consent * who performance status 0-2 * patients is considered to be mentally and physically ft for chemotherapy as judged by oncologist * adequate hematological, hepatic and renal function (wbc ≥ 3.0 x 109/l, neu ≥ 1.5 x 109/l, platelet count ≥ 100 x 109/l, renal clearance ≥ 50 ml/min, bilirubin ≤ 3x normal value, aspartate transaminase/alanine transaminase (ast/alt) ≤ 2,5x normal value) exclusion criteria: * t4 inoperable tumor - extensive growth into cranial part of the sacrum (above s3) or the lumbosacral nerve roots * metastatic or recurrent rectal cancer * other co-existing malignancy or malignancy within the past 5 years, with the exception of adequately treated in situ carcinoma of the cervix or basal cell carcinoma of the skin * chronic bowel inflammatory disease * pregnant or lactating patient * significant heart disease (uncontrolled hypertension despite of medication (\> 150/100 mmhg), new york heart association (nyha) class iii or iv heart disease,unstable angina or myocardial infarction within the past 1 year prior the study entry, history of significant ventricular arrhythmia requiring treatment) * inability to consciously sign the consent form due to physical or psychological disabilities

Keywords: rectal carcinoma preoperative radiochemotherapy imrt sib